Dallas TX, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 in Snowbird, UT. About Enovis Enovis™ (NYSE: ENOV) is a global medical technology innovator dedicated to improving lives by developing clinically differentiated solutions that enhance patient outcomes an ...

Core Viewpoint - Enovis Corporation will host an investor conference call and live webcast to discuss its fourth quarter and full year 2025 financial results on February 26, 2026, at 8:30 a.m. Eastern Time [1] Group 1: Conference Call/Webcast Information - Investors can access the live webcast via a link on the Enovis website, and participants can join the call by dialing (833) 685-0901 for U.S. callers and (412) 317-5715 for international callers [2] - A replay of the call will be available on the Enovis website later that day [2] Group 2: About Enovis - Enovis Corporation is an innovation-driven medical technology growth company focused on developing clinically differentiated solutions that improve patient outcomes and transform workflows [3] - The company offers a wide range of products, services, and integrated technologies aimed at supporting active lifestyles in orthopedics and beyond [3] - Enovis shares are listed on the New York Stock Exchange under the symbol ENOV [3] Group 3: Availability of Information - Enovis routinely announces material information to investors through SEC filings, press releases, public conference calls, webcasts, and its Investor Relations website [4] - The company encourages investors and the media to review the information shared on its Investor Relations website [4]

Enovis Corporation (NYSE:ENOV) is one of the best cheap stocks poised to skyrocket. On January 6, BTIG initiated coverage of Enovis Corporation (NYSE:ENOV) with a Buy rating and a $41 price target. The positive stance underscores the research firm’s confidence about the company’s long-term prospects as it offers a range of orthopedic care from prevention to surgical and post-surgical recovery. Enovis Corporation (ENOV): Orthopedic Innovation and Growth Potential Drive Analyst Confidence 15 African Countr ...

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.Here's the latest list of major oversold players ...

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.Here's the latest list of major oversold players ...

Core Thesis - Enovis Corporation is viewed positively due to its dual-engine economic model that combines a high-margin implant franchise with a lower-margin prevention and recovery business, which is expected to drive growth and stability in revenue streams [1][2]. Business Model - Enovis operates in the musculoskeletal healthcare sector, focusing on proprietary orthopedic implants for surgeries, which generate durable revenue due to high switching costs and surgeon loyalty [2][3]. - The prevention and recovery segment includes braces and therapy devices, increasingly bundled with the MotionMD software platform to create a more stable revenue stream through workflow integration [3]. Competitive Position - Enovis competes against larger companies like Stryker and Zimmer Biomet but leverages specialization and agility to fill market gaps through targeted acquisitions, such as LimaCorporate [4]. - The company is in an aggressive scaling phase, supported by significant investments in R&D and inventory, although this is accompanied by elevated leverage that may limit financial flexibility [4]. Management Strategy - Management focuses on organic growth, margin expansion, and successful integration of acquisitions, prioritizing these over short-term GAAP earnings, with a view towards deleveraging as a critical future milestone [5]. - The investment case relies on effective integration, sustained surgeon adoption, and disciplined capital allocation, indicating strong underlying economics but necessitating careful monitoring of execution and balance-sheet risks [5].

Company Overview - Enovis is an orthopedics company focused on mobility and the entire continuum of care, having built its business through over 20 acquisitions in the last five years [3] - The company generates approximately $2 billion in revenue, with a growth rate of around 6% [3] Business Segmentation - The business is evenly split between orthopedics implants and prevention and recovery [4] - Revenue is also approximately evenly divided between international markets and the U.S. [4] Financial Performance - Enovis raised its guidance on EBITDA and EPS recently, indicating positive financial outlook [3]

Summary of Enovis Conference Call Company Overview - **Company**: Enovis - **Industry**: Orthopedics - **Revenue**: Approximately $2 billion with a growth rate of around 6% [4][5] - **Focus**: Mobility and the continuum of care, with a balanced portfolio in orthopedic implants and prevention/recovery [4][5] Key Points Growth and Financial Performance - Enovis raised guidance on EBITDA and EPS, indicating positive financial momentum [5] - The company is experiencing growth driven by a mix of acquisitions and organic growth, with a core growth rate of about 6% excluding M&A [7] - Gross margins improved from approximately 14% to 18%, with a pathway to reach 20% [7] - The prevention and recovery (P&R) business has shifted from low single-digit growth to mid-single-digit growth [8] Strategic Focus - Enovis is concentrating on commercial execution, innovation, and financial discipline post-acquisitions [6] - The company aims to embed a "One Enovis" mindset to enhance collaboration and operational efficiency [9] - Continuous improvement and lean methodologies are being implemented across the organization [10] Product Portfolio and Innovation - Enovis has launched several new products, including the EMPOWR knee and ManiFuse, which are expected to drive future growth [11][29] - The company is leveraging its acquisitions to enhance product offerings and market reach, particularly in the shoulder and extremities segments [28][29] - The introduction of the ARVIS 2.0 robotic system is anticipated to support implant sales, although it will not be a standalone revenue line [34][36] Market Position and Competitive Advantage - Enovis has established a strong market presence, with significant brand loyalty in the P&R segment, particularly with the DonJoy brand [5][13] - The company is positioned to capitalize on trends in mobility health, including gut health, brain health, and overall mobility [10] Financial Goals and Cash Flow - Enovis aims for a free cash flow conversion of over 25% in 2026, with a long-term goal of 70% [16][51] - The company is focused on reducing integration costs and improving working capital efficiency to enhance cash flow generation [51][52] - Adjusted EBITDA and EPS are expected to improve, driven by a favorable product mix and cost management [25][26] Challenges and Considerations - The company experienced a slight softness in sales towards the end of the year, attributed to timing issues with ordering patterns [22] - Tariff impacts are expected to be slightly negative in 2026, but Enovis is confident in its ability to mitigate these effects [48][50] Future Outlook - Enovis is targeting mid-single-digit organic growth for 2026, with potential for higher growth driven by improved commercial execution and product introductions [20][30] - The company is committed to maintaining a disciplined approach to capital allocation and margin expansion as it continues to integrate acquisitions [41][45] Additional Insights - The integration of the LimaCorporate acquisition is progressing well, with expectations to achieve $40 million in cost synergies [40] - Enovis is focusing on organic R&D capabilities, moving away from reliance on acquisitions for innovation [42][44] - The company is actively working on improving its sales organization and targeting strategies to enhance market penetration [31][32]

2026 JP Morgan Healthcare Conference Damien McDonald Chief Executive Officer Ben Berry Chief Financial Officer Kyle Rose Vice President, Investor Relations Presentation Title is set in ALL CAPS Short description is set in sentence case This presentation includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Enovis' plans, g ...

Core Insights - Enovis Corporation will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 4:30 p.m. PST [1] - The company focuses on developing clinically differentiated medical technology solutions to enhance patient outcomes and restore motion [2] Company Overview - Enovis is a global innovator in medical technology, dedicated to improving lives through advanced healthcare solutions [2] - The company collaborates with leading health professionals to provide smarter, personalized, and effective care while enhancing operational efficiency for surgeons and clinicians [2] - Enovis solutions positively impact the well-being of millions of patients globally [2] Information Availability - Enovis regularly announces material information through SEC filings, press releases, public conference calls, webcasts, and its Investor Relations website [3] - The company encourages stakeholders to review the information shared on its Investor Relations website for potentially material updates [3]